Vertex Pharmaceuticals Inc
VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 15/3037% above fair value
$553.15−5.73 (-1.03%)
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals UTB by Year
UTB — Interest and penalties recognized in tax expense ($M) ($M)
Vertex Pharmaceuticals UTB: $13.1M in FY2025, down 131.6% from a year earlier.
Latest, FY2025
13.1
Period ended Dec 31, 2025
Change on a year earlier
-131.6%
-41.5 in FY2024
History
9 years
Since FY2015
Sources
7
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-13) ↗
Reported in Form 10-K Note (Income Taxes).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | UTB — Interest and penalties recognized in tax expense ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 13.1 | -131.6% | Form 10-K (filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | -41.5 | -148.9% | Form 10-K (filed 2026-02-13) ↗ |
| FY2023 | Dec 31, 2023 | 84.9 | +132.0% | Form 10-K (filed 2026-02-13) ↗ |
| FY2022 | Dec 31, 2022 | 36.6 | – | Form 10-K (filed 2025-02-13) ↗ |
| FY2021 | Dec 31, 2021 | 0 | – | Form 10-K (filed 2024-02-15) ↗ |
| FY2020 | Dec 31, 2020 | 0 | – | Form 10-K (filed 2023-02-10) ↗ |
| FY2017 | Dec 31, 2017 | 0 | – | Form 10-Q (filed 2018-10-25) ↗ |
| FY2016 | Dec 31, 2016 | 0 | – | Form 10-Q (filed 2017-10-30) ↗ |
| FY2015 | Dec 31, 2015 | 0 | – | Form 10-Q (filed 2016-10-31) ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals UTB ($M), annual FY2015–FY2025 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/utb-int-exp
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.